We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Silica Nanoparticles Adapted to Deliver Water-Insoluble Cancer Drugs

By Biotechdaily staff writers
Posted on 21 Jun 2007
Cancer researchers have found a way to administer hydrophobic chemotherapeutic drugs that does not require dissolving the medication in toxic solvents.

Investigators at the Jonsson Cancer Center (Los Angeles, CA, USA) used the pores of fluorescent mesoporous (i.e., containing pores with diameters between 2 and 50 nm) silica nanoparticles to sequester the hydrophobic anticancer drug camptothecin (CPT). More...
This drug and its derivatives are considered to be among the most effective of the currently available anticancer drugs. Although studies have demonstrated their effectiveness against a number of different types of cancer cells in vitro, clinical application of CPT in humans has only been carried out with derivatives that have improved water solubility.

Results published in the June 2007 issue of the journal Small showed that silica nanoparticles containing CPT were taken up by cancer cells, which then began to die. "In order to be used on humans, current cancer therapies such as CPT or Taxol, which are poorly water-soluble, must be mixed with organic solvents in order to be delivered into the body,” said senior author Dr. Fuyuhiko Tamanoi, professor of microbiology, immunology, and molecular genetics at the Jonsson Cancer Center. "These elements produce toxic side effects and in fact decrease the potency of the cancer therapy. Silica nanomaterials show promise for delivering camptothecin and other water-insoluble drugs. We have successfully loaded hydrophobic anticancer drugs into mesoporous nanoparticles and delivered them into human cancer cells to induce cell death.”


Related Links:
Jonsson Cancer Center

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.